SOURCE: IO NewsWire

IO NewsWire

January 27, 2011 15:09 ET

(NASDAQ: KERX) Rated a "BUY" by 5 Wall Street Firms

Note to Editors: The Following Is an Investment Opinion Being Issued by the IO News Wire

NEW YORK, NY--(Marketwire - January 27, 2011) - Keryx Biopharmaceuticals (NASDAQ: KERX) is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease.

Keryx currently has 2 late-stage Phase III drugs, Zerenex and Perifosine, with the FDA under a Special Protocol Assessment (SPA) declaration. A "SPA" is a declaration from the FDA that a proposed Phase III trial's design, clinical endpoints, and statistical analyses are acceptable for FDA approval.

A Phase III approval of both drugs should push Keryx over analyst price targets which are currently between $8 and $10 a share. Currently, Keryx is rated a "BUY" by 5 leading Wall Street firms.

To view the entire article written on Keryx Biopharmaceutical, please visit:

www.proactivenewsroom.com/Blog/bid/58771/Keryx-Biopharmaceuticals-KERX-2-promising-Phase-III-compounds

Other active stocks are GlaxoSmithKline (NYSE: GSK), Novartis AG (NYSE: NVS) and Bristol Myers Squibb Co (NYSE: BMY)

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact Information